Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind Placebo-controlled Study to Assess the Safety and Efficacy of Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care in Patients Hospitalized for Babesiosis

NCT06207370 is registered in ClinicalTrials.gov with 60 Degrees Pharmaceuticals LLC as lead sponsor.

NCT NCT06207370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06207370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind Placebo-controlled Study to Assess the Safety and Efficacy of Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care in Patients Hospitalized for Babesiosis
Lead sponsor
60 Degrees Pharmaceuticals LLC
Phase
Phase 2
Overall status
Recruiting
Start date
June 17, 2024
Completion date
July 1, 2027
Enrollment
33 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

babesiosis